natgillin/translations-raw huggingface dataset:
Subsequent infusionsb
nadaljnje infuzijeb
Subsequent maintenance therapy can be administered in one of two ways:
Poznejše vzdrževalno zdravljenje se lahko izvaja na enega izmed dveh načinov:
Subsequent metabolism of the 2-oxo-clopidogrel intermediate metabolite results in formation of the active metabolite, a thiol derivative of clopidogrel.
Nadaljnja presnova vmesnega presnovka 2- oksoklopidogrela povzroči nastanek aktivnega presnovka, ki je tiolski derivat klopidogrela.
Subsequent testing should be conducted annually in children while they are receiving Revestive.
Poznejše testiranje moramo pri otrocih, ki prejemajo zdravilo Revestive, opravljati enkrat na leto.
Subsequent vitamin B12 injections may be given on the same day as pemetrexed.
Kasnejše injekcije vitamina B12 se lahko daje isti dan kot pemetreksed.
Subsequently the dose may be individually adjusted every 1 to 2 weeks to maintain the average neutrophil count between 1.5 x 109/l and 10 x 109/l.
Nato je možno odmerek individualno prilagajati na 1 do 2 tedna, za ohranjanje povprečnega števila nevtrofilcev med 1,5 x 109/l in 10 x 109/l.
Subsequently the efficacy was confirmed in several field studies in cats and dogs, which were conducted in several different European geographical locations.
Zatem je bila potrjena v več terenskih študijah z mačkami in psi, ki so bile izvedene na številnih različnih območjih po Evropi.
Subsequently, all patient samples were re-tested using the bioMerieux (bMx) THxID BRAF validated assay, which has CE marking.
Vzorce vseh bolnikov so nato ponovno testirali z validiranim testom bioMerieux (bMx) THxID BRAF, ki ima oznako CE.
Subsequently, all patient samples were re-tested using the CE-marked bioMerieux (bMx) THxID BRAF validated assay.
Vzorce vseh bolnikov so nato ponovno testirali z validiranim testom bioMerieux (bMx) ThxID BRAF, ki ima oznako CE.
Subsequently, antithrombin activity should be checked 1-2 times a day and dose adjustments made accordingly.
Aktivnost antitrombina morate nato preverjati 1- do 2-krat dnevno in odmerek ustrezno prilagajati.
Subsequently, antithrombin activity should be checked 1-2 times a day and dose adjustments made accordingly.
Aktivnost antitrombina morate nato preverjati 1–2 dnevno in odmerek ustrezno prilagajati.
Subsequently, exenatide concentrations of approximately 300 pg/ml were maintained indicating that steady state was achieved.
Koncentracija eksenatida približno 300 pg/ml je znak, da je bilo doseženo ravnovesno stanje.
Subsequently, in the initial phase of treatment, the activity of protein C is more rapidly suppressed than that of the procoagulant factors.
Zaradi tega v začetni fazi zdravljenja aktivnost proteina C zavremo hitreje kot aktivnost prokoagulantnih faktorjev.
Subsequently, remove the needle from the vial.
Nato iglo odstranite iz viale.
Subsequently, the dose may be individually adjusted every 1-2 weeks to maintain the average neutrophil count between 1.5 x 109/L and 10 x 109/L.
Nato je mogoče odmerek individualno prilagajati na vsak(a) 1-2 tedna, da se ohrani povprečno število nevtrofilcev med 1,5 x 109/L in 10 x 109/L.
Subsequently, the marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.
Imetnik dovoljenja za promet z zdravilom mora redno posodobljena poročila o varnosti zdravila za to zdravilo predložiti v skladu z zahtevami, določenimi v seznamu referenčnih datumov Unije (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES in objavljenem na evropskem spletnem portalu o zdravilih.
Subsequently, the marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.>
Zatem jih mora predložiti v skladu z zahtevami, določenimi v seznamu referenčnih datumov Unije (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES in objavljenem na evropskem spletnem portalu o zdravilih.
Subsequently, the Myocet infusion should be restarted in a different vein than that in which the extravasation has occurred.
Zatem zdravilo Myocet infundirajte naprej, vendar ne v veno, pri kateri je prišlo do ekstravazacije.
Subsequently, the patient will have an injection under the skin once a week.
Nato bo bolnik enkrat tedensko prejemal injekcijo v podkožje.
Subsequently, using the same criteria, patients who tolerate an axitinib dose of 7 mg twice daily may have their dose increased to a maximum of 10 mg twice daily.
Pozneje je ob uporabi enakih meril mogoče pri bolnikih, ki prenašajo aksitinib v odmerku 7 mg dvakrat na dan, odmerek povečati na največ 10 mg dvakrat na dan.
Substance dependence.
odvisnosti od substanc
Substance overdose
preveliko odmerjanje učinkovine
Substance-specific side effects:
Neželeni učinki, značilni za učinkovino
Substances added to Victoza may cause degradation of liraglutide.
Snovi, dodane zdravilu Victoza, lahko povzročijo razgradnjo liraglutida.
Substances added to Xultophy may cause degradation of the active substances.
Dodajanje drugih učinkovin zdravilu Xultophy lahko povzroči razgradnjo zdravilnih učinkovin.
Substances metabolised by cytochrome P450
Snovi, ki jih presnavlja citokrom P450
Substances shown to be predominately excreted either via the active organic anionic pathway, or by glomerular filtration are unlikely to yield clinically significant interactions with lamivudine.
Malo je verjetno, da bi učinkovine, za katere se je izkazalo, da se primarno izločajo po aktivni organski anionski poti ali z glomerularno filtracijo, povzročile klinično pomembne interakcije z lamivudinom.
Substances that are inducers of CYP3A4 activity (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital, fosphenytoin, primidone or Hypericum perforatum, also known as St. John’s Wort) may significantly reduce exposure to Glivec, potentially increasing the risk of therapeutic failure.
Snovi, ki inducirajo aktivnost CYP3A4 (na primer deksametazon, fenitoin, karbamazepin, rifampicin, fenobarbital, fosfenitoin, primidon ali Hypericum perforatum, znan tudi pod imenom šentjanževka), lahko znatno zmanjša izpostavljenost zdravilu Glivec in s tem potencialno poveča tveganje za neuspešnost zdravljenja.
Substances that are inducers of CYP3A4 activity (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital, fosphenytoin, primidone or Hypericum perforatum, also known as St. John’s Wort) may significantly reduce exposure to imatinib , potentially increasing the risk of therapeutic failure.
Snovi, ki inducirajo aktivnost CYP3A4 (na primer deksametazon, fenitoin, karbamazepin, rifampicin, fenobarbital, fosfenitoin, primidon ali Hypericum perforatum, znan tudi pod imenom šentjanževka), lahko znatno zmanjša izpostavljenost imatinibu in s tem potencialno poveča tveganje za neuspešnost zdravljenja.
Substances that are inducers of CYP3A4 activity (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital, fosphenytoin, primidone or Hypericum perforatum, also known as St. John’s Wort) may significantly reduce exposure to imatinib, potentially increasing the risk of therapeutic failure.
Snovi, ki inducirajo aktivnost CYP3A4 (na primer deksametazon, fenitoin, karbamazepin, rifampicin, fenobarbital, fosfenitoin, primidon ali Hypericum perforatum, znan tudi pod imenom šentjanževka), lahko znatno zmanjša izpostavljenost imatinibu in s tem potencialno poveča tveganje za neuspešnost zdravljenja.
Substances that are inducers of CYP3A4 activity (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital, fosphenytoin, primidone or Hypericum perforatum, also known as St. John’s Wort) may significantly reduce exposure to imatinib, potentially increasing the risk of therapeutic failure.
Snovi, ki inducirajo aktivnost CYP3A4 (na primer deksametazon, fenitoin, karbamazepin, rifampicin, fenobarbital, fosfenitoin, primidon ali Hypericum perforatum, znan tudi pod imenom šentjanževka), lahko znatno zmanjšajo izpostavljenost imatinibu in s tem potencialno povečajo tveganje za neuspešnost zdravljenja.
Substances that are inducers of CYP3A4 activity may increase metabolism and decrease gefitinib plasma concentrations and thereby reduce the efficacy of gefitinib.
Snovi, ki inducirajo CYP3A4, lahko povečajo presnovo in zmanjšajo koncentracijo gefitiniba v plazmi ter tako zmanjšajo učinkovitost gefitiniba.
Substances that are inducers of CYP3A4 or PgP may decrease everolimus blood concentrations by increasing metabolism or the efflux of everolimus from intestinal cells.
Snovi, ki inducirajo CYP3A4 ali P-glikoprotein, lahko znižajo koncentracijo everolimusa v krvi, ker povečujejo njegov metabolizem ali njegov transport iz črevesnih celic.
Substances that are inducers of CYP3A4, such as rifampicin, carbamazepine, barbiturates and St John’s wort (Hypericum perforatum) are likely to decrease the plasma concentrations of darifenacin.
Snovi, ki so induktorji CYP3A4, na primer rifampicin, karbamazepin, barbiturati in šentjanževka (Hypericum perforatum), bodo verjetno znižale plazemske koncentracije darifenacina.
Substances that are inhibitors of CYP3A4 or PgP may increase everolimus blood concentrations by decreasing metabolism or the efflux of everolimus from intestinal cells.
Snovi, ki zavirajo CYP3A4 ali P-glikoprotein, lahko zvišajo koncentracijo everolimusa v krvi, ker zmanjšujejo njegov metabolizem ali njegov transport iz črevesnih celic.
Substances that are substrates of CYP2B6 and CYP2C9 enzymes with narrow therapeutic range (e.g. warfarin, acenocoumarol, efavirenz, methadone) or BCRP substrates with narrow therapeutic range (e.g. methotrexate, mitoxantrone, irinotecan, topotecan) should be avoided.
Uporabi snovi, ki imajo ozko terapevtsko okno in so substrati encimov CYP2B6 oziroma CYP2C9 (kot so varfarin, acenokumarol, efavirenz, metadon) ali substrati prenašalca BCRP (kot so metotreksat, mitoksantron, irinotekan in topotekan), se je treba izogibati.
Substances that inhibit the cytochrome P450 isoenzyme CYP3A4 activity (e.g. protease inhibitors such as indinavir, lopinavir/ritonavir, ritonavir, saquinavir, telaprevir, nelfinavir, boceprevir; azole antifungals including ketoconazole, itraconazole, posaconazole, voriconazole; certain macrolides such as erythromycin, clarithromycin and telithromycin) could decrease metabolism and increase imatinib concentrations.
Snovi, ki zavirajo aktivnost izoencima CYP3A4 citokroma P450 (na primer proteazni inhibitorji, kot so indinavir, lopinavir/ritonavir, ritonavir, sakvinavir, telaprevir, nelfinavir, boceprevir; azolni antimikotiki, med drugim ketokonazol, itrakonazol, pozakonazol, vorikonazol; nekateri makrolidi, n.pr. eritromicin, klaritromicin in telitromicin), bi lahko zmanjševale presnovo in zviševale koncentracije imatiniba.
Substances that inhibit the cytochrome P450 isoenzyme CYP3A4 activity (e.g. protease inhibitors such as indinavir, lopinavir/ritonavir, ritonavir, saquinavir, telaprevir, nelfinavir, boceprevir; azole antifungals including ketoconazole, itraconazole, posaconazole, voriconazole; certain macrolides such as erythromycin, clarithromycin and telithromycin) could decrease metabolism and increase imatinib concentrations.
Snovi, ki zavirajo aktivnost izoencima CYP3A4 citokroma P450 (na primer zaviralci proteaze, kot so indinavir, lopinavir/ritonavir, ritonavir, sakvinavir, telaprevir, nelfinavir, boceprevir; azolni antimikotiki vključno s ketokonazolom, itrokonazolom, posakonazolom, vorikonazolom; določenimi antimikotiki kot so eritromicin, klaritromicin in telitromicin), bi lahko zmanjševale presnovo in zviševale koncentracije imatiniba.
Substances that may enhance the blood-glucose-lowering activity and increase susceptibility to hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors (MAOIs), pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics.
Med zdravili, ki lahko stopnjujejo učinek znižanja glukoze v krvi in zvečajo nagnjenost k hipoglikemiji, so peroralni antidiabetiki, zaviralci angiotenzinske konvertaze (ACE), dizopiramid, fibrati, fluoksetin, zaviralci monoaminooksidaze (MAO), pentoksifilin, propoksifen, salicilati in sulfonamidni antibiotiki.
Substances that may have their serum concentrations altered by ponatinib
Snovi, ki jim lahko ponatinib spremeni koncentracije v serumu
Substances that may reduce the blood-glucose-lowering activity include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, estrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotic medicinal products (e.g. olanzapine and clozapine).
Med zdravili, ki lahko zmanjšajo učinek znižanja glukoze v krvi, so kortikosteroidi, danazol, diazoksid, diuretiki, glukagon, izoniazid, derivati fenotiazina, somatropin, simpatikomimetiki (npr. adrenalin, salbutamol, terbutalin), ščitnični hormoni, estrogeni, progestini (npr. v peroralnih kontraceptivih), zaviralci proteaz in atipični antipsihotiki (npr. olanzapin in klozapin).
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline) thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and olanzapine) and protease inhibitors.
Med zdravili, ki lahko zmanjšajo učinek znižanja glukoze v krvi, so kortikosteroidi, danazol, diazoksid, diuretiki, glukagon, izoniazid, estrogeni in progestogeni, fenotiazinski derivati, somatropin, simpatikomimetiki (npr. adrenalin, salbutamol, terbutalin), ščitnični hormoni, atipični antipsihotiki (npr. klozapin in olanzapin) in proteazni inhibitorji.
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens, progestogens, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and olanzapine) and protease inhibitors.
Med zdravili, ki lahko zmanjšajo učinek znižanja glukoze v krvi, so kortikosteroidi, danazol, diazoksid, diuretiki, glukagon, izoniazid, estrogeni, progestogeni, fenotiazinski derivati, somatropin, simpatikomimetiki (npr. adrenalin, salbutamol, terbutalin), ščitnični hormoni, atipični antipsihotiki (npr. klozapin in olanzapin) in zaviralci proteaz.
Substances transported by P-glycoprotein or other transporters
Učinkovine, ki jih prenaša P-glikoprotein ali drugi prenašalci
Substances which are potent inhibitors of enzymes that metabolise medicinal products (see section 5.2)
Učinkovine, ki so močni zaviralci encimov, ki presnavljajo zdravila (glejte poglavje 5.2)
Substances with variable effects on the clearance of CHCs
Učinkovine z različnimi učinki na očistek CHC
Substantial cross-resistance was observed between most elvitegravir-resistant HIV-1 isolates and raltegravir, and between emtricitabine-resistant isolates and lamivudine.
Znatno navzkrižno rezistanco so opazili med večino izolatov HIV-1, rezistentnih na elvitegravir, in raltegravirjem ter med izolati, rezistentnimi na emtricitabin, in lamivudinom.
Substantial decrease in lopinavir
Bistveno zmanjšanje
Substantial decrease in lopinavir exposure.
Bistveno zmanjšanje izpostavljenosti
Substantial differences may exist in the pharmacokinetic profile of immediate-release fentanyl medicinal products, which result in clinically important differences in the rate and extent of absorption of fentanyl.
V farmakokinetičnem profilu zdravil s takojšnjim sproščanjem fentanila so lahko precejšnje razlike, kar povzroča klinično pomembne razlike v hitrosti in obsegu absorpcije fentanila.
Substantial improvement
Bistveno izboljšanje
substantial increases in
zvišanja izpostavljenosti
substantial increases in progesterone exposure are unknown.
zvišanja izpostavljenosti
Substitutions observed in clinical isolates (rtT184A, C, F, G, I, L, M or S; rtS202 C, G or I; and/or rtM250I, L or V) further decreased entecavir susceptibility 16- to 741-fold relative to wild-type virus.
Substitucije, ki so jih opazili pri kliničnih izolatih (rtT184A, C, F, G, I, L, M ali S; rtS202 C, G ali I; in/ali rtM250I, L ali V), v primerjavi z divjim tipom virusa še dodatno zmanjšajo občutljivost za entekavir za 16- do 741- krat.
Substitutions only observed in combinations with other emerging substitutions at one or more of the NS3 positions 80, 122, 155 and/or 168.
Substitucije, ki so jih opažali samo v kombinacijah z drugimi novimi substitucijami na enem ali več položajih NS3: 80, 122, 155 in/ali 168.
Substitutions were observed in combination with other emergent substitutions at NS3 position R155 or D168.
Substitucije so opažali v kombinaciji z drugimi nastalimi substitucijami na mestih R155 in D168 NS3.
substrate and is associated with QT
zdravilom Invirase/ritonavirjem
Substrates for CYP3A4: Co-administration is contraindicated with the following agents that are substrates for CYP3A4 and that have narrow therapeutic windows: terfenadine, astemizole, cisapride, amiodarone, quinidine, ergot derivatives, pimozide, oral midazolam, triazolam, alfuzosin, and sildenafil when used to treat pulmonary arterial hypertension (see section 4.3).
Substrati za CYP3A4: sočasno jemanje sledečih snovi, ki so substrati za CYP3A4 in, ki imajo ozko terapevtsko okno, je kontraindicirano: terfenadin, astemizol, cisaprid, amiodaron, kvinidin, derivati ergot, pimozid, peroralni midazolam, triazolam, alfuzosin in sildenafil, kadar se uporablja za zdravljenje pljučne arterijske hipertenzije (glejte poglavje 4.3).
Substrates for CYP3A: Co-administration is contraindicated with the following agents that are substrates for CYP3A4 and that have narrow therapeutic windows terfenadine, astemizole, cisapride, amiodarone, quinidine, ergot derivatives, pimozide, oral midazolam, triazolam, alfuzosin, and sildenafil when used to treat pulmonary arterial hypertension (see section 4.3).
Substrati za CYP3A4: sočasno jemanje sledečih snovi, ki so substrati za CYP3A4 in ki imajo ozko terapevtsko okno, je kontraindicirano: terfenadin, astemizol, cisaprid, amiodaron, kvinidin, derivati ergot, pimozid, peroralni midazolam triazolam, alfuzosin in sildenafil, kadar se uporablja za zdravljenje pljučne arterijske hipertenzije (glejte poglavje 4.3).
Substrates of OCT1
Substrati OCT1
Substudy Part 1
FK podštudija
Success a rate n/N (%)
topnja uspešnosti a n/N (%)
Success at Day 180*
Uspešnost na 180. dan
Success by Species
Uspešnost po vrstah
Success rate
Delež uspešnosti
Success rate (%)
Delež uspešnosti (%)
Success rate* %
Delež uspešnosti zdravljenja
Successful outcome in this section is defined as complete or partial response.
Uspešen izid je v tem delu opredeljen kot popoln ali delen odziv.
Successful treatment of VMA can help reverse disturbances of the vision caused by VMT, and prevent further loss of vision from untreated and progressive traction at the retina.
Uspešno zdravljenje vitreomakularne adhezije lahko pomaga odpraviti motnje vida zaradi vitreomakularne trakcije in preprečiti nadaljnjo izgubo vida zaradi nezdravljene in napredovale trakcije mrežnice.
Successful weight loss is not just about eating differently for a short period of time before reverting to your old habits.
Učinkovita izguba telesne mase ne pomeni zgolj spremembe prehranjevalnih navad za krajše obdobje, ki se nato povrnejo k vašim starim navadam.
Succinic acid Sodium hydroxide Sucrose Polysorbate 20
Sukcinska kislina Natrijev hidroksid Saharoza Polisorbat 20
Such a reaction is uncommon (may affect up to 1 in 100 people). if you are having radiation treatment in the vessels that supply blood to the heart (treatment called beta or gamma brachytherapy).
Takšne reakcije so občasne (pojavijo se lahko pri največ 1 od 100 bolnikov) če se zdravite z obsevanjem žil, ki dostavljajo kri do srca (zdravljenje se imenuje beta ali gama brahiterapija)
Such combinations should be avoided in known CYP2C9 poor metabolisers (see sections 4.2 and 5.2).
Pri bolnikih, za katere je znano, da slabo presnavljajo s CYP2C9, ne uporabljajte takšnih kombinacij (glejte poglavji 4.2 in 5.2).
Such complications rarely occur with the use of enoxaparin sodium in doses of 40 mg per day or less.
Takšni zapleti so redki, če je natrijev enoksaparinat uporabljen v odmerkih 40 mg enkrat na dan ali manjših.
Such dilutions with sodium chloride should be done in a syringe, pulling out the desired amount of Neurobloc into the syringe first, and then adding sodium chloride to the syringe.
Zdravilo razredčite z natrijevim kloridom v brizgi, najprej izvlecite potrebno količino zdravila NeuroBloc v brizgo, nato pa v brizgo dodajte natrijev klorid.
Such elevations appeared to have occurred early with eribulin treatment in cycle 1 – 2 for the majority of these patients and whilst thought likely to be a phenomenon of adaptation to eribulin treatment by the liver and not a sign of significant liver toxicity in most patients, hepatotoxicity has also been reported.
Pri večini teh bolnikov se je takšno zvišanje pojavilo zgodaj med zdravljenjem z eribulinom, v 1. ali 2. ciklu zdravljenja, in čeprav gre verjetno za fenomen prilagajanja jeter na zdravljenje z eribulinom, ne pa znak pomembne toksičnosti za jetra, so poročali tudi o hepatotoksičnosti.
Such evaluations indicate that sex does not affect the pharmacokinetics of rufinamide to a clinically relevant extent.
Takšne ocene kažejo, da spol ne vpliva v klinično pomembnem obsegu na farmakokinetiko rufinamida.
Such events might impact the ability to drive and use machines.
Takšni dogodki bi lahko vplivali na sposobnost vožnje in upravljanja s stroji.
Such exacerbations have been seen following discontinuation of emtricitabine treatment in HBV infected patients without concomitant HIV infection and have been detected primarily by serum alanine aminotransferase (ALT) elevations in addition to re-emergence of HBV DNA.
Takšno poslabšanje je bilo opaženo po prekinitvi zdravljenja z emtricitabinom pri bolnikih z okužbo HBV brez hkratne okužbe z virusom HIV in je bilo primarno odkrito s povišanjem serumskega nivoja alanin-aminotransferaze (ALT) z dodatnim ponovnim pojavom HBV DNA.
Such high doses were well-tolerated; however, these women had a shortened menstrual cycle (uterine bleeding occurring 2-3 days earlier than would be expected) and in some women, the duration of bleeding was prolonged, although not excessive in amount (spotting).
Tako visoke odmerke so dobro prenesle; vendar pa so poročale o skrajšanem menstruacijskem ciklusu (do menstrualne krvavitve je prišlo 2–3 dni bolj zgodaj kot je bilo pričakovano), pri nekaterih ženskah pa je bilo tudi trajanje krvavitve podaljšano, ni pa bila krvavitev bolj obilna (šibka krvavitev).
Such infants should be revaccinated at 12 to 15 months.
Te dojenčke je treba ponovno cepiti v starosti od 12 do 15 mesecev.
Such inhibitors include certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole), certain antibiotics (e.g. troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g. ritonavir, indinavir, boceprevir, and telaprevir), nicardipine, bromocriptine, cimetidine, and danazol.
Takšni zaviralci so nekateri antimikotiki (npr. klotrimazol, flukonazol, itrakonazol, vorikonazol), nekateri antibiotiki (npr. troleandomicin, telitromicin, klaritromicin), nekateri zaviralci proteaz (npr. ritonavir, indinavir, boceprevir, telaprevir), nikardipin, bromokriptin, cimetidin in danazol.